PD-L1 mediated the differentiation of tumor-infiltrating CD19⁺ B lymphocytes and T cells in Invasive breast cancer

References

• Cooper MD, Alder MN. The evolution of adaptive immune systems. Cell (2006); 124:815-22; PMID:16497590; http://dx.doi.org/10.1016/j.cell.2006.02.001
   PubMed Web of Science ®Google Scholar
• Jager E, Jager D, Knuth A. Clinical cancer vaccine trials. Curr Opin Immunol (2002); 14:178-82; PMID:11869889; http://dx.doi.org/10.1016/S0952-7915(02)00318-7
   PubMed Web of Science ®Google Scholar
• Yanaba K, Bouaziz JD, Matsushita T, Magro CM, St Clair EW, Tedder TF. B-lymphocyte contributions to human autoimmune disease. Immunol Rev (2008); 223:284-99; PMID:18613843; http://dx.doi.org/10.1111/j.1600-065X.2008.00646.x
   PubMed Web of Science ®Google Scholar
• Christensen JP, Kauffmann SO, Thomsen AR. Deficient CD4+ T cell priming and regression of CD8+ T cell functionality in virus-infected mice lacking a normal B cell compartment. J Immunol (2003); 171:4733-41; PMID:14568949; http://dx.doi.org/10.4049/jimmunol.171.9.4733
   PubMed Web of Science ®Google Scholar
• LeBien TW, Tedder TF. B lymphocytes: how they develop and function. Blood (2008); 112:1570-80; PMID:18725575; http://dx.doi.org/10.1182/blood-2008-02-078071
   PubMed Web of Science ®Google Scholar
• Hansen MH, Nielsen H, Ditzel HJ. The tumor-infiltrating B cell response in medullary breast cancer is oligoclonal and directed against the autoantigen actin exposed on the surface of apoptotic cancer cells. Proc Natl Acad Sci U S A (2001); 98:12659-64; PMID:11606714; http://dx.doi.org/10.1073/pnas.171460798
   PubMed Web of Science ®Google Scholar
• Inoue S, Leitner WW, Golding B, Scott D. Inhibitory effects of B cells on antitumor immunity. Cancer Res (2006); 66:7741-7; PMID:16885377; http://dx.doi.org/10.1158/0008-5472.CAN-05-3766
   PubMed Web of Science ®Google Scholar
• Tadmor T, Zhang Y, Cho HM, Podack ER, Rosenblatt JD. The absence of B lymphocytes reduces the number and function of T-regulatory cells and enhances the anti-tumor response in a murine tumor model. Cancer Immunol Immunother (2011); 60:609-19; PMID:21253724; http://dx.doi.org/10.1007/s00262-011-0972-z
   PubMed Web of Science ®Google Scholar
• Iwata Y, Matsushita T, Horikawa M, Dilillo DJ, Yanaba K, Venturi GM, Szabolcs PM, Bernstein SH, Magro CM, Williams AD et al. Characterization of a rare IL-10-competent B-cell subset in humans that parallels mouse regulatory B10 cells. Blood (2011); 117:530-41; PMID:20962324; http://dx.doi.org/10.1182/blood-2010-07-294249
   PubMed Web of Science ®Google Scholar
• Blair PA, Noreña LY, Flores-Borja F, Rawlings DJ, Isenberg DA, Ehrenstein MR, Mauri C. CD19(+)CD24(hi)CD38(hi) B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic lupus erythematosus patients. Immunity (2010); 32:129-40; PMID:20079667; http://dx.doi.org/10.1016/j.immuni.2009.11.009
   PubMed Web of Science ®Google Scholar
• Das A, Ellis G, Pallant C, Lopes AR, Khanna P, Peppa D, Chen A, Blair P, Dusheiko G, Gill U et al. IL-10-producing regulatory B cells in the pathogenesis of chronic hepatitis B virus infection. J Immunol (2012); 189:3925-35; PMID:22972930; http://dx.doi.org/10.4049/jimmunol.1103139
   PubMed Web of Science ®Google Scholar
• Mamula MJ. Editorial: B cells: not just making immunoglobulin anymore. Arthritis Rheumatol (2014); 66:2-5; PMID:24449569; http://dx.doi.org/10.1002/art.38208
   PubMed Web of Science ®Google Scholar
• Helal TE, Ibrahim EA, Alloub AI. Immunohistochemical analysis of tumor-infiltrating lymphocytes in breast carcinoma: relation to prognostic variables. Indian J Pathol Microbiol (2013); 56:89-93; PMID:24056641; http://dx.doi.org/10.4103/0377-4929.118676
   PubMed Web of Science ®Google Scholar
• Dorfman DM, Brown JA, Shahsafaei A, Freeman GJ. Programmed death-1 (PD-1) is a marker of germinal center-associated T cells and angioimmunoblastic T-cell lymphoma. Am J Surg Pathol (2006); 30:802-10; PMID:16819321; http://dx.doi.org/10.1097/01.pas.0000209855.28282.ce
   PubMed Web of Science ®Google Scholar
• Ren X, Akiyoshi K, Vandenbark AA, Hurn PD, Offner H. Programmed death-1 pathway limits central nervous system inflammation and neurologic deficits in murine experimental stroke. Stroke (2011); 42:2578-83; PMID:21737801; http://dx.doi.org/10.1161/STROKEAHA.111.613182
   PubMed Web of Science ®Google Scholar
• Park JJ, Omiya R, Matsumura Y, Sakoda Y, Kuramasu A, Augustine MM, Yao S, Tsushima F, Narazaki H, Anand S et al. B7-H1/CD80 interaction is required for the induction and maintenance of peripheral T-cell tolerance. Blood (2010); 116:1291-8; PMID:20472828; http://dx.doi.org/10.1182/blood-2010-01-265975
   PubMed Web of Science ®Google Scholar
• Ghebeh H, Mohammed S, Al-Omair A, Qattan A, Lehe C, Al-Qudaihi G, Elkum N, Alshabanah M, Bin Amer S, Tulbah A et al. The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors. Neoplasia (2006); 8:190-8; PMID:16611412; http://dx.doi.org/10.1593/neo.05733
   PubMed Web of Science ®Google Scholar
• Hua D, Sun J, Mao Y, Chen LJ, Wu YY, Zhang XG. B7-H1 expression is associated with expansion of regulatory T cells in colorectal carcinoma. World J Gastroenterol (2012); 18:971-8; PMID:22408358; http://dx.doi.org/10.3748/wjg.v18.i9.971
   PubMed Web of Science ®Google Scholar
• Chen Y, Wang Q, Shi B, Xu P, Hu Z, Bai L, Zhang X. Development of a sandwich ELISA for evaluating soluble PD-L1 (CD274) in human sera of different ages as well as supernatants of PD-L1+ cell lines. Cytokine (2011); 56:231-8; PMID:21733718; http://dx.doi.org/10.1016/j.cyto.2011.06.004
   PubMed Web of Science ®Google Scholar
• Flies DB, Sandler BJ, Sznol M, Chen L. Blockade of the B7-H1/PD-1 pathway for cancer immunotherapy. Yale J Biol Med (2011); 84:409-21; PMID:22180678
   PubMedGoogle Scholar
• Gao Q, Wang XY, Qiu SJ, Yamato I, Sho M, Nakajima Y, Zhou J, Li BZ, Shi YH, Xiao YS et al. Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma. Clin Cancer Res (2009); 15:971-9; PMID:19188168; http://dx.doi.org/10.1158/1078-0432.CCR-08-1608
   PubMed Web of Science ®Google Scholar
• Mauri C, Blair PA. Editorial: regulatory B cells: are we really ready to manipulate them for the benefit of patients with autoimmune diseases? Arthritis Rheumatol (2014); 66:1982-3; PMID:24729488; http://dx.doi.org/10.1002/art.38667
   PubMed Web of Science ®Google Scholar
• Ghebeh H, Barhoush E, Tulbah A, Elkum N, Al-Tweigeri T, Dermime S. FOXP3+ Tregs and B7-H1+/PD-1+ T lymphocytes co-infiltrate the tumor tissues of high-risk breast cancer patients: Implication for immunotherapy. BMC Cancer (2008); 8:57; PMID:18294387; http://dx.doi.org/10.1186/1471-2407-8-57
   PubMed Web of Science ®Google Scholar
• Picchianti Diamanti A, Rosado MM, Scarsella M, Germano V, Giorda E, Cascioli S, Laganà B, D'Amelio R, Carsetti R. Abatacept (cytotoxic T lymphocyte antigen 4-immunoglobulin) improves B cell function and regulatory T cell inhibitory capacity in rheumatoid arthritis patients non-responding to anti-tumour necrosis factor-alpha agents. Clin Exp Immunol (2014); 177:630-40; PMID:24773026; http://dx.doi.org/10.1111/cei.12367
   PubMed Web of Science ®Google Scholar
• DiLillo DJ, Weinberg JB, Yoshizaki A, Horikawa M, Bryant JM, Iwata Y, Matsushita T, Matta KM, Chen Y, Venturi GM et al. Chronic lymphocytic leukemia and regulatory B cells share IL-10 competence and immunosuppressive function. Leukemia (2013); 27:170-82; PMID:22713648; http://dx.doi.org/10.1038/leu.2012.165
   PubMed Web of Science ®Google Scholar
• Olkhanud PB, Damdinsuren B, Bodogai M, Gress RE, Sen R, Wejksza K, Malchinkhuu E, Wersto RP, Biragyn A. Tumor-evoked regulatory B cells promote breast cancer metastasis by converting resting CD4(+) T cells to T-regulatory cells. Cancer Res (2011); 71:3505-15; PMID:21444674; http://dx.doi.org/10.1158/0008-5472.CAN-10-4316
   PubMed Web of Science ®Google Scholar
• Qiu YH, Zhang X, Ji Y, Ju S, Wang T. Preparation of functional monoclonal antibody against human CD28 and analysis of its biological feature. Chin J Cell Mol Immunol (2001); 17:368-70
   Google Scholar
• Zhou ZH, Wang JF, Wang YD, Qiu YH, Pan JZ, Xie W, Jiang LY, Klein B, Zhang XG. An agonist anti-human CD40 monoclonal antibody that induces dendritic cell formation and maturation and inhibits proliferation of a myeloma cell line. Hybridoma (1999); 18:471-8; PMID:10626675
   PubMed Web of Science ®Google Scholar
• Khokher S, Qureshi MU, Chaudhry NA. Comparison of WHO and RECIST criteria for evaluation of clinical response to chemotherapy in patients with advanced breast cancer. Asian Pac J Cancer Prev (2012); 13:3213-8; PMID:22994736; http://dx.doi.org/10.7314/APJCP.2012.13.7.3213
   PubMed Web of Science ®Google Scholar
• Adegboyega TO, Landercasper J, Linebarger JH, Johnson JM, Andersen JJ, Dietrich LL, Driscoll CD, Raghavendra M, Madadi AR, Al-Hamadani M et al. Institutional review of compliance with NCCN guidelines for breast cancer: lessons learned from real-time multidimensional synoptic reporting. J Natl Compr Canc Netw (2015); 13:177-83; PMID:25691610
   PubMed Web of Science ®Google Scholar
• Zagouri F, Liakou P, Bartsch R, Peccatori FA, Tsigginou A, Dimitrakakis C, Zografos GC, Dimopoulos MA, Azim HA Jr. Discrepancies between ESMO and NCCN breast cancer guidelines: An appraisal. Breast, (2015); 24(4):513-23; PMID:25818651; http://dx.doi.org/10.1016/j.breast.2015.02.031
   PubMed Web of Science ®Google Scholar
• Theriault RL, Carlson RW, Allred C, Anderson BO, Burstein HJ, Edge SB, Farrar WB, Forero A, Giordano SH, Goldstein LJ et al. Breast cancer, version 3.2013: featured updates to the NCCN guidelines. J Natl Compr Canc Netw (2013); 11:753-60; quiz 761; PMID:23847214
   PubMed Web of Science ®Google Scholar
• Xie F, Wang Q, Chen Y, Gu Y, Mao H, Zeng W, Zhang X. Costimulatory molecule OX40/OX40L expression in ductal carcinoma in situ and invasive ductal carcinoma of breast: an immunohistochemistry-based pilot study. Pathol Res Pract (2010); 206:735-9; PMID:20634005; http://dx.doi.org/10.1016/j.prp.2010.05.016
   PubMed Web of Science ®Google Scholar
• Zhou Y, Chen YJ, Bai LX, Zhu GC, Wang XF, Zhang XG. Preparation and characterization of three novel monoclonal antibodies against human PD-L1. Chin J Cell Mol Immunol (2011); 27:1208-11; PMID:22078450
   PubMedGoogle Scholar